Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Would you recommend SGLT2 inhibitors for patients with sickle cell nephropathy and severely increased albuminuria despite the potential medication associated risk for vaso-occlusive crises?
Related Questions
Do you recommend temporarily holding SGLT2 inhibitors in patients with CKD who are undergoing CT imaging with intravenous contrast?
What are your criteria for starting tolvaptan in adult patients diagnosed with autosomal dominant polycystic kidney disease?
How do you approach hematuria in a patient with diabetic nephropathy?
Do you temporarily hold ESAs for your patients with kidney disease who have an upcoming surgical procedure with the goal of reducing the risk for DVTs?
Would you start an SGLT2 inhibitor in patients with diabetic kidney disease who also have a history of prior toe amputation?
How do you tailor protein intake recommendations for older patients with stages 3-5 non-dialysis dependent CKD, considering the unique metabolic and physiologic factors that influence protein metabolism in this population?
Would you avoid SGLT2 inhibitors in patients with urinary incontinence requiring incontinence briefs due to concern with genitourinary hygiene and risk for infections?
Do you offer home administration of ESAs for your patients with anemia of chronic kidney disease?
At what serum bicarbonate level do you initiate alkali therapy for patients with chronic kidney disease?
What is your preferred iron loading strategy for patients with anemia of chronic kidney disease?
